News

Article

Dr Mark Fendrick, PAN Foundation's Dan Klein Commend Trump Administration's Drug Rebate Proposal

In a commentary, Dan Klein, president and chief operating officer of the Patient Access Network Foundation, and A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan, called the Trump administration's recent drug rebate proposal an opportunity to significantly lower out-of-pocket precription drug costs for Medicare patients.

In a commentary, Dan Klein, president and chief operating officer of the Patient Access Network Foundation, and A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan, called the Trump administration's recent drug rebate proposal an opportunity to significantly lower out-of-pocket precription drug costs for Medicare patients. The pair called the proposal spot on for both improving access and affordability but note that accomplishing these goals will require support from all key stakeholders, including patient advocates, pharmaceutical companies, health plans, and pharmaceutical benefit managers.

However, they caution that, like most things in healthcare, there is more complexity to the proposal that initially meets the eye. Read more here.

Related Videos
Dr Raymond Osarogiagbon
Christine Funke, MD
Dr Raymond Osarogiagbon
5 experts are featured in this series
5 experts are featured in this series
Harry Travis sitting for a video interview
Dr Raymond Osarogiagbon
Naim Alkhouri, MD
Joe DePinto, MBA, sitting for a video interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo